News

Bristol Myers Squibb (NYSE:BMY) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a forward P/E of 9 that screams cheap. But the underlying numbers tell a different story. That low multiple is cheap for a reason. Bristol Myers is running headfirst into a generic cliff that the ... Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

AbbVie (ABBV) is back in focus after a cluster of regulatory decisions, including FDA approval of DECNUPAZ for a rare blood cancer and European green lights for AQUIPTA and new VENCLYXTO combinations. See our latest analysis for AbbVie. The recent approvals have coincided with building momentum in the stock, with a 1 month share price return of 10.83% and a 1 year total shareholder return of 23.60%, while the 3 year total shareholder return sits at 83.11%. If these developments caught your...

A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, ... SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc. (NYSE:ABBV) announced on June 2 that the European Commission approved AQUIPTA® for the acute treatment of migraine in adults with or without aura, to be taken as needed. Management stated that the approval marks the second indication for AQUIPTA in […]

AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.

The United States market has shown a remarkable 26% increase over the past year, despite remaining flat over the last week, with expectations for earnings to grow by 16% annually in the coming years. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities that align with these growth prospects and current market stability.

In the last week, the United States market has stayed flat, yet it has experienced a significant 26% increase over the past year with earnings forecasted to grow by 16% annually. In such a robust environment, identifying stocks that are estimated to be below their intrinsic value can offer investors potential opportunities for growth and value appreciation.

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.

AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.

The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.

The market is underestimating these companies' long-term prospects.

Over the last 7 days, the United States market has risen by 1.2%, contributing to a significant 27% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, identifying stocks that are potentially trading below their estimated value can offer investors opportunities for growth and diversification.

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes

The United States market has shown robust performance recently, climbing 1.2% in the last week and rising an impressive 27% over the past year, with earnings expected to grow by 17% annually. In this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for investors seeking value amidst overall market growth.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

AbbVie's shareholders can sleep easy.

The United States market has shown impressive performance, rising 1.6% over the last week and climbing 28% in the past year, with earnings forecasted to grow by 17% annually. In light of these conditions, identifying stocks that may be priced below their estimated value can offer opportunities for investors seeking potential growth at a reasonable cost.

AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to […]

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) is among the best immunology stocks. TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and fast-progressing blood […]

Over the last 7 days, the United States market has risen 1.6%, contributing to a 28% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and value appreciation.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Glenmark Pharmaceuticals Ltd (BOM:532296) reports robust Q4 growth, achieves debt-free status, and sets ambitious targets for FY27.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease.